Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immutep Ltd (PRRUF)
OTHER OTC:PRRUF
Holding PRRUF?
Track your performance easily
PRRUF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.15 - $0.38
Previous Close$0.21
Volume1.00K
Average Volume (3M)1.75K
Market Cap
$310.08M
Enterprise Value$193.62M
Total Cash (Recent Filing)AU$181.88M
Total Debt (Recent Filing)AU$1.59M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Feb 20, 2025EPS Estimate
-$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding879,089,453
10 Day Avg. Volume100
30 Day Avg. Volume1,750
Standard Deviation0.32
R-Squared0.00041
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)209.01
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$0.58Price Target Upside184.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Immutep Ltd News
PremiumCompany Announcements
Immutep’s Cancer Trial Shows Promising Survival Results
PremiumCompany Announcements
Immutep Ltd Reports Promising Results in Sarcoma Trial
PremiumCompany Announcements
Immutep Ltd Reports Positive Advances in Cancer Trials
PremiumCompany Announcements
Immutep Limited Announces 2024 AGM DetailsOwnership Overview
1.03% Insiders
0.02% Mutual Funds
― Other Institutional Investors
98.80% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PRRUF FAQ
What was Immutep Ltd’s price range in the past 12 months?
Immutep Ltd lowest stock price was $0.15 and its highest was $0.38 in the past 12 months.
What is Immutep Ltd’s market cap?
Currently, no data Available
When is Immutep Ltd’s upcoming earnings report date?
Immutep Ltd’s upcoming earnings report date is Feb 20, 2025 which is in 95 days.
How were Immutep Ltd’s earnings last quarter?
Immutep Ltd released its earnings results on Aug 28, 2024. The company reported -$0.012 earnings per share for the quarter, beating the consensus estimate of -$0.012 by <$0.001.
Is Immutep Ltd overvalued?
According to Wall Street analysts Immutep Ltd’s price is currently Undervalued.
Does Immutep Ltd pay dividends?
Immutep Ltd does not currently pay dividends.
What is Immutep Ltd’s EPS estimate?
Immutep Ltd’s EPS estimate is -$0.01.
How many shares outstanding does Immutep Ltd have?
Immutep Ltd has 1,454,567,900 shares outstanding.
What happened to Immutep Ltd’s price movement after its last earnings report?
Immutep Ltd reported an EPS of -$0.012 in its last earnings report, beating expectations of -$0.012. Following the earnings report the stock price went up 4%.
Which hedge fund is a major shareholder of Immutep Ltd?
Currently, no hedge funds are holding shares in PRRUF
---
Immutep Ltd Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$0.58 (184.38% Upside)
$0.58 (184.38% Upside)
Blogger Sentiment
Bullish
PRRUF Sentiment 97%
Sector Average 73%
Sector Average 73%
Insider Transactions
Bought Shares
Worth $6.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
14.05%
12-Months-Change
Fundamentals
Return on Equity
-25.75%
Trailing 12-Months
Asset Growth
37.16%
Trailing 12-Months
Company Description
Immutep Ltd
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
---
PRRUF Stock 12 Month Forecast
Average Price Target
$0.58
▲(184.38% Upside)
Technical Analysis
Immutep
―
Northwest Biotherapeutics
―
Cyclacel Pharmaceuticals
―
TRACON Pharmaceuticals
―
Best Analysts Covering PRRUF
1 Year
1 Year Success Rate
5/14 ratings generated profit
1 Year Average Return
-2.64%
reiterated a buy rating 2 months ago
Copying Melissa Benson's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of -2.64% per trade.
---